68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells

68%接受ELI-002治疗的患者产生了细胞毒性mKRAS特异性CD4+T细胞

84% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD8+ T cells

84%接受ELI-002治疗的患者产生了细胞毒性mKRAS特异性CD8+T细胞

The majority of ELI-002-treated patients tested had antigen spreading where induced T cells targeted additional patient-specific tumor mutations beyond mKRAS

大多数接受ELI-002治疗的患者都有抗原扩散，其中诱导的T细胞靶向mKRAS以外的其他患者特异性肿瘤突变

The majority of patients who received a ELI-002 booster dose were observed to have durable mKRAS-specific T cell response with increased memory T cell phenotype

观察到大多数接受ELI-002加强剂量的患者具有持久的mKRAS特异性T细胞反应，记忆T细胞表型增加

Preclinical studies of ELI-007 and ELI-008 demonstrated that AMP vaccination resulted in a 42-fold to a several-hundred-fold increased immune response when compared to conventional vaccines

ELI-007和ELI-008的临床前研究表明，与常规疫苗相比，AMP疫苗接种导致免疫反应增加了42倍至数百倍

Initial ELI-002 7P clinical data expected to be presented in the second quarter of 2024

最初的ELI-002 7P临床数据预计将于2024年第二季度提交

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research (“AACR”) Annual Meeting, taking place in San Diego, California from April 5-10, 2024.

波士顿，2024年4月5日（环球通讯社）--Elicio Therapeutics，Inc.（纳斯达克：ELTX，“Elicio Therapeutics”或“Elicio”），一家临床阶段的生物技术公司，开发用于治疗癌症的新型免疫疗法管道，今天宣布将在即将于2024年4月5日至10日在加利福尼亚州圣地亚哥举行的美国癌症研究协会（“AACR”）年会上为所有研究候选人分享管道更新。

Among the data presented will be updated immunogenicity data from the ongoing Phase 1 (AMPLIFY-201) study of ELI-002, an off-the-shelf investigational therapeutic cancer vaccine for patients with mutant Kirsten rat sarcoma (“mKRAS”)-driven pancreatic and colorectal cancers. Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared..

在提供的数据中，将有来自正在进行的ELI-002第一阶段（AMPLIFY-201）研究的最新免疫原性数据，ELI-002是一种用于突变型Kirsten大鼠肉瘤（“mKRAS”）驱动的胰腺癌和结直肠癌患者的现成研究性治疗性癌症疫苗。还将共享关于候选疫苗ELI-007和ELI-008的临床前数据，分别针对BRAF和p53驱动的癌症的研究性肽疫苗。。

In the first-in-human, Phase 1 (AMPLIFY-201) study, ELI-002 was given as adjuvant treatment for patients with high relapse-risk mKRAS-driven colorectal cancer (“CRC”) and pancreatic ductal adenocarcinoma (“PDAC”). A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.   ELI-002 demonstrated several key advantages, including lymph node-targeted vaccine design, potent immunogenicity with balanced CD4+ and CD8+ T cell responses, HLA-agnostic activity, and targeting of mKRAS antigens critical for tumor survival.

在第一项人类第一阶段（AMPLIFY-201）研究中，ELI-002被用作高复发风险mKRAS驱动的结直肠癌（“CRC”）和胰腺导管腺癌（“PDAC”）患者的辅助治疗。大多数接受加强免疫的患者相对于基线维持或增加了mKRAS特异性T细胞应答。ELI-002表现出几个关键优势，包括淋巴结靶向疫苗设计，具有平衡的CD4+和CD8+T细胞应答的有效免疫原性，HLA不可知活性以及靶向对肿瘤存活至关重要的mKRAS抗原。

The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype. Regulatory T cell responses were not detected. Antigen spreading was observed following ELI-002 vaccination, with patient-specific tumor neoantigen-directed T cell responses detected in the majority of evaluated patients using direct ex vivo immunogenicity assays..

由ELI-002产生的mKRAS特异性CD4和CD8 T细胞表现出增加的细胞毒性功能和有利的记忆表型的发展。未检测到调节性T细胞应答。在ELI-002疫苗接种后观察到抗原扩散，使用直接离体免疫原性测定法在大多数评估患者中检测到患者特异性肿瘤新抗原定向的T细胞应答。。

'Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses. With longer follow-up, we observed response durability and added antigen-spreading to the mechanism of ELI-002, where we saw additional personal neoantigen responses join together with mutated KRAS responses creating a precision response that may lead to enhanced clinical activity,” said Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer.

“发表在《自然医学》上的早期数据表明，我们现成的淋巴结靶向癌症疫苗候选物ELI-002可诱导记忆T细胞反应。随着随访时间的延长，我们观察到反应的持久性，并将抗原扩散添加到ELI-002的机制中，在那里我们看到额外的个人新抗原反应与突变的KRAS反应结合在一起，产生了精确的反应，可能会导致临床活动的增强，”医学博士、Elicio执行副总裁、研发负责人和首席医疗官Christopher Haqq说。

“Following positive early findings from the 2-peptide formulation of ELI-002, we initiated a randomized Phase 2 study of our 7-peptide formulation, ELI-002 7P, in adjuvant pancreatic cancer (NCT05726864). We expect to share interim 7-peptide ELI-002 data from the Phase 1A arm in the second quarter of 2024.”.

“根据ELI-002的2肽制剂的积极早期发现，我们启动了一项针对辅助性胰腺癌（NCT05726864）的7肽制剂ELI-002 7P的随机2期研究。我们预计在2024年第二季度分享1A期臂的中期7肽ELI-002数据。”。

Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics, added, “These preclinical data demonstrate that ELI-007 and ELI-008 induce strong tumor antigen-specific T cell responses targeting BRAF and p53 mutations, respectively. ELI-007 and ELI-008 induced highly potent and functional T cell responses, often ten to a hundred-fold higher than comparator.

Elicio Therapeutics首席科学官Peter DeMuth博士补充道：“这些临床前数据表明，ELI-007和ELI-008分别诱导针对BRAF和p53突变的强烈肿瘤抗原特异性T细胞应答。ELI-007和ELI-008诱导了高效和功能性T细胞应答，通常比对照组高十到一百倍。

These data build on previous data showing that the AMP strategy can improve the potency of vaccine immunotherapy by delivering vaccine components directly to the lymph nodes, the ‘command center’ of the immune system. These data support the broad applicability of the technology and represent promising therapeutic product opportunities targeting mutations shared in a large fraction of human solid cancers.”.

这些数据基于先前的数据，表明AMP策略可以通过将疫苗成分直接递送至淋巴结（免疫系统的“指挥中心”）来提高疫苗免疫疗法的效力。这些数据支持该技术的广泛适用性，并代表了针对大部分人类实体癌共有的突变的有希望的治疗产品机会。”。

Poster Presentation Summary

海报展示摘要

Presentation Title: Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer

演讲标题：ELI-002 2P在AMPLIFY-201中的持久免疫原性：胰腺癌和结直肠癌中靶向淋巴结的mKRAS特异性两亲性疫苗

Session Title: First-in-Human Phase I Clinical Trials 1

课程名称：首次人类I期临床试验1

Session Date and Time: Monday, April 8, 2024, 1:30 PM – 5:00 PM PT

会议日期和时间：2024年4月8日，星期一，下午1:30-下午5:00

ELI-002 2P consists of 2 Amph-modified mKRAS peptide antigens, Amph-G12D and Amph-G12R (Amph-Peptides 2P), and an Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909).

ELI-002 2P由2种Amph修饰的mKRAS肽抗原Amph-G12D和Amph-G12R（Amph肽2P）以及Amph修饰的免疫刺激性寡核苷酸佐剂（Amph-CpG-7909）组成。

ELI-002 2P was administered as an adjuvant treatment for patients with high relapse-risk mutant KRAS PDAC and CRC.

ELI-002 2P被用作高复发风险突变KRAS PDAC和CRC患者的辅助治疗。

25 patients received ELI-002 2P at 1.4 mg of Amph-Peptides 2P and Amph-CpG-7909 at 5 escalating dose levels: 0.1, 0.5, 2.5, 5, and 10 mg.

25名患者接受了1.4 mg Amph肽2P和Amph-CpG-7909的ELI-002 2P，剂量水平分别为0.1、0.5、2.5、5和10 mg。

Peripheral blood and circulating tumor DNA (“ctDNA”) or serum tumor antigen were collected longitudinally to assess T cell immunogenicity and reductions in clinical tumor biomarkers.

纵向收集外周血和循环肿瘤DNA（“ctDNA”）或血清肿瘤抗原，以评估T细胞免疫原性和临床肿瘤生物标志物的减少。

A majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline. Durable responses were associated with increased memory T cell phenotype compared to baseline.

大多数接受ELI-002加强免疫的患者相对于基线维持或增加了mKRAS特异性T细胞应答。与基线相比，持久反应与记忆T细胞表型增加有关。

ELI-002 induced increased mKRAS-specific CD4 and CD8 T cells with cytotoxic function, associated with increased memory phenotype in a majority of patients.

ELI-002诱导具有细胞毒性功能的mKRAS特异性CD4和CD8 T细胞增加，与大多数患者的记忆表型增加有关。

CD4+ T regulatory cells were not induced after ELI-002 2P immunization.

ELI-002 2P免疫后未诱导CD4+T调节细胞。

Antigen spreading was observed with T cell responses to patient-specific tumor mutations (not mKRAS) after ELI-002 2P vaccination in a majority of patients tested.

在大多数接受测试的患者中，ELI-002 2P疫苗接种后，T细胞对患者特异性肿瘤突变（非mKRAS）的反应观察到抗原扩散。

Data demonstrated several advantages of ELI-002 including lymph node-targeted vaccine design, potent immunogenicity with durable and balanced CD4+ and CD8+ T cell responses, increased T cell cytotoxic function, and antigen spreading to induce T cells targeting additional tumor mutations beyond mKRAS..

数据证明了ELI-002的几个优点，包括淋巴结靶向疫苗设计，具有持久和平衡的CD4+和CD8+T细胞应答的有效免疫原性，增加的T细胞细胞毒性功能，以及抗原扩散以诱导T细胞靶向mKRAS以外的其他肿瘤突变。。

Presentation Title:AMP-peptide vaccination against mutant BRAF epitopes promotes lymph node delivery to generate potent, functional T cell immunity

演讲标题：针对突变BRAF表位的AMP肽疫苗接种可促进淋巴结传递，从而产生有效的功能性T细胞免疫

Session Title: Vaccines, Antigens, and Antigen Presentation 1

课程名称：疫苗，抗原和抗原呈递1

Session Date and Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM PT

Session Date and Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM PT

Our preclinical program, ELI-007, is an investigational multivalent lymph node–targeted AMP peptide vaccine comprised of the V600E and V600K mutant antigens, developed to target BRAF gene mutations.

我们的临床前计划ELI-007是一种研究性多价淋巴结靶向AMP肽疫苗，由V600E和V600K突变抗原组成，旨在靶向BRAF基因突变。

AMP-immunization generated robust in vivo immune responses yielding strong T cell activation against mBRAF epitopes.

AMP免疫产生强大的体内免疫应答，产生针对mBRAF表位的强T细胞活化。

Lymph node-targeted AMP-vaccination resulted in a 19-fold increase in immune response after only 3 doses and a 42-fold increase after 5 doses when compared to conventional comparator vaccines.

与常规比较疫苗相比，淋巴结靶向AMP疫苗接种仅在3剂后导致免疫应答增加19倍，在5剂后增加42倍。

Induced T cells were polyfunctional exhibiting the production of multiple effector cytokines (IFNγ, TNFα, IL2, GM-CSF) as well as cytotoxic molecules (Granzyme B) important in the lysis of tumor cells.

诱导的T细胞是多功能的，表现出产生多种效应细胞因子（IFNγ，TNFα，IL2，GM-CSF）以及在肿瘤细胞裂解中重要的细胞毒性分子（颗粒酶B）。

Substantial populations of mBRAF-specific T cells were found patrolling peripheral organs like the lung, which is one of the predominant sites for metastatic spread in melanoma and colorectal carcinoma.

发现大量mBRAF特异性T细胞在肺等外周器官中巡逻，肺是黑色素瘤和结直肠癌转移扩散的主要部位之一。

Presentation Title: AMP-peptide vaccination against multiple p53 mutant epitopes promotes lymph node delivery to generate potent, functional T cell immunity

演讲标题：针对多个p53突变表位的AMP肽疫苗接种可促进淋巴结传递，从而产生有效的功能性T细胞免疫

Session Title: Vaccines, Antigens, and Antigen Presentation 1

课程名称：疫苗，抗原和抗原呈递1

Session Date and Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM PT

Session Date and Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM PT

Our preclinical program, ELI-008, is an investigational multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations.

我们的临床前计划ELI-008是一种针对p53热点突变的多价淋巴结靶向AMP肽疫苗。

AMP-immunization generated robust immune responses yielding strong T cell activation against common p53 hot spot mutations (R248W, R248Q, R175H, R273H, R273C, R282W, G245S, Y220C, C135Y, R158H, H214R).

AMP免疫产生强大的免疫应答，产生针对常见p53热点突变（R248W，R248Q，R175H，R273H，R273C，R282W，G245S，Y220C，C135Y，R158H，H214R）的强烈T细胞活化。

Potent T cell responses were observed after only two doses with AMP-p53 R248W, which were further improved after a third bi-weekly dose. For multiple p53 mutations, ELI-008 demonstrated a several-hundred-fold increase over conventional comparator vaccines.

仅在两次剂量的AMP-p53 R248W后观察到有效的T细胞反应，在第三次两周剂量后进一步改善。对于多个p53突变，ELI-008比常规比较疫苗显示出数百倍的增加。

Induced T cells were polyfunctional exhibiting production of multiple effector cytokines (IFNγ, TNFα, IL2, GM-CSF) and showed high cytotoxic potential by secreting large quantities of Granzyme B and effectively killing target cells in vivo.

诱导的T细胞是多功能的，表现出多种效应细胞因子（IFNγ，TNFα，IL2，GM-CSF）的产生，并通过分泌大量颗粒酶B并在体内有效杀死靶细胞而显示出高的细胞毒性潜力。

Substantial populations of p53-specific T cells were found patrolling peripheral organs like the lung, which is one of the predominant sites for the metastatic spread of many cancers.

发现大量p53特异性T细胞在肺等外周器官中巡逻，肺是许多癌症转移扩散的主要部位之一。

About ELI-002

关于ELI-002

Our lead product candidate, ELI-002, is a structurally novel investigational AMP cancer vaccine that targets cancers that are driven by mutations in the mKRAS-gene—a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with our AMP platform consisting of AMP-modified mutant KRAS peptide antigens and an AMP-modified CpG adjuvant that is available as an off-the-shelf subcutaneous administration. .

我们的主要候选产品ELI-002是一种结构新颖的研究性AMP癌症疫苗，其靶向由mKRAS基因突变驱动的癌症，mKRAS基因是许多人类癌症的普遍驱动因素。ELI-002由两个强大的组件组成，它们是由我们的AMP平台构建的，该平台由AMP修饰的突变KRAS肽抗原和AMP修饰的CpG佐剂组成，该佐剂可作为现成的皮下给药。。

ELI-002 2P (2 peptide formulation) is currently being studied in an ongoing Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy (NCT04853017). ELI-002 7P (7 peptide formulation) is currently being studied in a Phase 2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer (NCT05726864).

ELI-002 2P（2肽制剂）目前正在进行一项正在进行的1期（AMPLIFY-201）试验中，该试验针对高复发风险的mKRAS驱动的实体瘤患者，在手术和化疗后进行 （NCT04853017）。ELI-002 7P（7肽制剂）目前正在mKRAS驱动的胰腺癌患者的2期（AMPLIFY-7P）试验中进行研究（NCT05726864）。

The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations present in 25% of all solid tumors, thereby increasing the potential patient population for ELI-002 and potentially reducing the chance of bypass resistance mechanisms. .

ELI-002 7P制剂旨在针对25%的实体瘤中存在的七种最常见的KRAS突变提供免疫应答覆盖，从而增加ELI-002的潜在患者人群，并可能降低旁路耐药机制的机会。。

About ELI-007 and ELI-008

关于ELI-007和ELI-008

Our preclinical programs, ELI-007 and ELI-008, are being evaluated in studies funded by the Gastro-Intestinal (“GI”) Research Foundation with the aim of developing multivalent cancer vaccines targeting several mutations.

我们的临床前项目ELI-007和ELI-008正在由胃肠道（“GI”）研究基金会资助的研究中进行评估，旨在开发针对几种突变的多价癌症疫苗。

ELI-007 is an investigational multivalent lymph node–targeted AMP peptide vaccine comprised of the V600E and V600K mutant antigens, which make up >95% of all BRAF-driven cancers in humans, representing up to 1.5 million cancer incidences worldwide each year. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.

ELI-007是一种研究性多价淋巴结靶向AMP肽疫苗，由V600E和V600K突变抗原组成，占人类所有BRAF驱动的癌症的95%以上，每年全球癌症发病率高达150万。BRAF基因是驱动细胞生长和分裂的细胞内信号传导途径的一部分。

BRAF mutations can lead to uncontrolled cell growth and ultimately cancer.   .

BRAF突变可导致不受控制的细胞生长并最终导致癌症。。

ELI-008 is an investigational multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication and cell division. Mutations in the p53 protein lead to uncontrolled tumor progression and growth.

ELI-008是一种针对p53热点突变的研究性多价淋巴结靶向AMP肽疫苗。p53是一种抑制肿瘤的蛋白质，可控制细胞周期，DNA复制和细胞分裂。p53蛋白的突变导致不受控制的肿瘤进展和生长。

Similar to KRAS, p53 mutations are present in a broad spectrum of cancer types, accounting for >30% of solid tumors. .

与KRAS相似，p53突变存在于广泛的癌症类型中，占实体瘤的30%以上。。

In preclinical models, ELI-007 and ELI-008 have shown strong T cell activation and demonstrated strong induction of tumor-antigen-specific T cell responses.

在临床前模型中，ELI-007和ELI-008显示出强烈的T细胞活化，并显示出对肿瘤抗原特异性T细胞应答的强烈诱导。

About Elicio Therapeutics

关于Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with Amphiphile (“AMP”) Technology which allows for therapeutic payloads to be delivered directly to the lymph nodes, enhancing the immune system’s cancer-fighting capabilities.

Elicio Therapeutics，Inc.（纳斯达克股票代码：ELTX）是一家临床阶段生物技术公司，致力于开发新型淋巴结靶向免疫疗法，用于治疗一些最具侵袭性的癌症。通过结合免疫学和免疫治疗方面的专业知识，Elicio利用两亲（“AMP”）技术利用免疫系统的天然力量，使治疗有效载荷直接传递到淋巴结，增强免疫系统的抗癌能力。

By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality, and durability of the immune response to drive antitumor activity.

通过将癌症免疫疗法靶向免疫反应的核心，AMP旨在优化淋巴结教育，激活和扩增癌症特异性T细胞的天然能力，这对于识别和消除肿瘤细胞至关重要。AMP旨在同步这些高效位点的免疫力，旨在增强免疫反应的幅度，效力，质量和持久性，以驱动抗肿瘤活性。

The Company’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com. .

该公司的研发渠道包括现成的治疗性癌症疫苗ELI-002（针对mKRAS驱动的癌症）以及ELI-007和ELI-008（分别针对BRAF驱动的癌症和p53热点突变）。欲了解更多信息，请访问www.elicio.com。

Cautionary Note on Forward-Looking Statements

关于前瞻性陈述的警示说明

Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (“PSLRA”). These include statements regarding Elicio’s planned clinical programs, including planned clinical trials, the potential of Elicio’s product candidates, including the potential for the AMP strategy to improve the potency of vaccine immunotherapy, the broad applicability of Elicio’s technology and the potential therapeutic product opportunities; the expected participation and presentation at upcoming conferences, and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.

本函件中包含的关于非历史事实的某些陈述是《1934年证券交易法》（经修订）第21E节和《1995年私人证券诉讼改革法》（“PSLRA”）所指的前瞻性陈述。这些包括关于Elicio计划的临床计划的声明，包括计划的临床试验，Elicio候选产品的潜力，包括AMP策略提高疫苗免疫疗法效力的潜力，Elicio技术的广泛适用性以及潜在的治疗产品机会；在即将举行的会议上的预期参与和陈述，以及有关管理层对未来的意图、计划、信念、期望或预测的其他声明，因此，请注意不要过度依赖这些声明。

No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

无法保证前瞻性陈述，实际结果可能与预测结果存在重大差异。Elicio没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。我们使用诸如“预期”、“相信”、“计划”、“期望”、“项目”、“未来”、“打算”、“可能”、“将会”、“应该”、“可能”、“估计”、“预测”、“潜在”、“继续”、“指导”等词语，以及类似的表达方式来识别这些前瞻性声明，这些声明旨在包含在PSLRA的安全港条款中。

Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s plans .

此类前瞻性声明基于我们的预期，涉及风险和不确定性；因此，由于许多因素，包括但不限于Elicio的计划，实际结果可能与报表中明示或暗示的结果存在重大差异。

New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

新的因素不时出现，我们不可能预测所有这些因素，也无法评估每个因素对业务的影响，或者任何因素或因素组合可能导致实际结果与任何前瞻性陈述中包含的结果存在重大差异的程度。

These risks are more fully discussed in the Annual Report on Form 10-K that was filed with the SEC on March 29, 2024, under the heading “Risk Factors”, and any subsequent reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release.

这些风险在2024年3月29日提交给美国证券交易委员会的10-K表格年度报告中以“风险因素”为题进行了更全面的讨论，随后的任何报告和其他文件也不时提交给美国证券交易委员会。本版本中包含的前瞻性声明基于截至本版本发布之日Elicio可获得的信息。

Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law..

Elicio没有义务更新此类前瞻性声明，以反映本发布日期后的事件或情况，除非法律要求。。

Media Contact

媒体联系人

Kristin Politi

克里斯汀警方

LifeSci Communications

LifeSci通信

kpoliti@lifescicomms.com

kpoliti@lifescicomms.com

646-876-4783

646-876-4783

Investor Relations Contact

投资者关系联系人

Heather DiVecchia

Heather DiVecchia

Elicio Therapeutics

精英疗法

IR@elicio.com

IR@elicio.com

857-209-0153

857-209-0153